Representation of Mallinckrodt Pharmaceuticals in Precedent-Setting Opioid Litigation

Bass, Berry & Sims represents Mallinckrodt Pharmaceuticals in numerous separate opioid cases filed in state courts across Tennessee, Virginia and Kentucky. One of the Tennessee cases is a precedent-setting, opioid-related case for the country; it is presently on appeal to the Tennessee Supreme Court upon the appellate court’s reversal of a grant of a dispositive motion to our client. A second case was set to go to trial at the time of a recent bankruptcy filing involving a global settlement of opioid claims that stayed the case as to our client.

Mallinckrodt Pharmaceuticals (NYSE: MNK) is a primarily generic pharmaceutical manufacturer of opioids.

You Also May Be Interested In:

  • Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

    We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many...
    Client Type: Private Company
  • Represented Boston Children’s Hospital with intellectual property, business, and government contracting issues associated with VaccineFinder

    We represented Boston Children's Hospital with intellectual property, business, and government contracting issues associated with VaccineFinder. We also assisted Boston...
    Client Type: Private Company
  • We represented ClearPoint Neuro, Inc. (f/k/a MRI Interventions, Inc.), a global therapy-enabling platform company providing navigation and delivery to the brain, in its $17.5 million strategic investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management, with $10.0 million of notes funded by PTC and $7.5 million of notes funded by Petrichor. With the net proceeds from the sale of the notes to PTC and Petrichor, the ClearPoint Neuro intends to repay in full its existing secured indebtedness, and to fund product commercialization, internal research and development, and general corporate requirements. Additionally, we advised ClearPoint Neuro in the draw of $7.5 million additional proceeds from Petrichor in December 2020. ClearPoint Neuro  intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts.

    We represented ClearPoint Neuro, Inc. (f/k/a MRI Interventions, Inc.), a global therapy-enabling platform company providing navigation and delivery to the...
    Client Type: Private Company